BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-66@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: ModernaTX\, Inc. — mRNA-1018-H5 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study of mRNA-1018-H5 Pandemic In
 fluenza Vaccine in Healthy Adults.\nSource: https://clinicaltrials.gov/stu
 dy/NCT07496450\nhttps://catalystbrief.girapphe.com/e/66?lang=en\nNot inves
 tment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/66?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
